Archived News
2006
Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia
Ascenta Therapeutics Presents New Preclinical Data on Mdm2 Inhibitor Portfolio Compound MI-63
Return to top of page
Ascenta Ascending - A Model of Efficiency in Drug Development - Company Profiled in the San Diego Union Tribune
Return to top of page
Ascenta Appointment of Craig Kussman, MBA, as Chief Financial Officer of Ascenta Therapeutics
Return to top of page
Ascenta Profiled in July/August Edition of Windhover's Start Up Magazine
Return to top of page
Ascenta's Oral Pan-Bcl-2 Inhibitor Ranked in Top Ten Leading Cancer Projects by Windhover Information, Inc.
June 5, 2006
AT-101, Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting
Return to top of page
Dajun Yang, MD, PhD of Ascenta Therapeutics Presents Award at 11th Annual Chinese Biopharmaceutical Association Conference
Return to top of page
Ascenta Therapeutics Hosts Shanghai Delegation During Visit to San Diego, California
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at BIO 2006 in Chicago
Return to top of page
April 4, 2006
Ascenta Therapeutics Novel MDM2-p53 Inhibitors Demonstrate Preclinical Single Agent Efficacy in Multiple Tumor Models
Return to top of page
Appointment of Lance Leopold, M.D., as Vice-President of Clinical Development
Return to top of page
